Nabriva Therapeutics Inc. (NASDAQ: NBRV) stock plunged by 5.88% at last close whereas the NBRV stock price tends to rise by 1.79% in the after-hours trading session. Nabriva Therapeutics is a pharmaceutical business focused on the discovery and marketing of novel anti-infective medicines for the treatment of severe illnesses.
NBRV stock’ Significant Development
The first evidence of XENLETA’s anti-inflammatory efficacy was released by Nabriva Therapeutics (lefamulin). The nonclinical research was released in the peer-reviewed journal PLOS ONE and was titled “Anti-inflammatory efficacy of lefamulin vs azithromycin and dexamethasone in vivo and in vitro in a lipopolysaccharide-induced lung neutrophilia mice model.”
XENLETA is the first pleuromutilin to be licensed for the treatment option of community-acquired bacterial pneumonia (CABP) in adults. XENLETA effectively reduced inflammation induced by the migration of neutrophils (a kind of white blood cell) in the lungs of mice in this nonclinical investigation of inflammatory lung disease. Importantly, XENLETA decreased pro-inflammatory cytokines to levels equivalent to dexamethasone (a powerful corticosteroid) and higher than azithromycin which is a macrolide antibiotic widely used for its anti-inflammatory effects.
Dr. Thomas File, Chair of the Infectious Disease Division at Summa Health stated,
These findings are significant because they show that lefamulin has anti-inflammatory effects in addition to its anti-infective properties. The ability to treat two major issues, bacterial infection, and concomitant inflammation, with a single drug, might make therapy for patients with acute lung illnesses more convenient.
Steve Gelone, Nabriva’s President and COO, and a co-author of the study commented,
Lung infection causes an immediate inflammatory response that might worsen a patient’s clinical program and make therapy more challenging. They think that an agent with powerful antibacterial and anti-inflammatory characteristics might provide doctors with a unique therapeutic alternative for their patients. They’re excited to keep testing XENLETA’s potential to reduce inflammation and learn more about its therapeutic uses.
